Eleison Pharmaceuticals, Inc.n(“Eleison”), a specialty pharmaceutical company developing life-saving therapeutics fornrare cancers, and China Oncology Focus Limited (“COF”), a subsidiary of Lee’snPharmaceutical Holdings Ltd. (“Lee’s Pharm”) have jointly announced that a partnership isnformed, to develop and commercialize the pancreatic drug candidate glufosfamide for thenChinese market and other countries of southeast Asia.
Eleison Pharmaceuticals LLC, a specialty pharmaceutical companyndeveloping life-saving therapeutics for rare cancers, has announced it has received approval from thenChina Food and Drug Administration (the “CFDA”) to enroll patients in China under Eleison’s ongoingnPhase III clinical trial of Glufosfamide.
Eleison Pharmaceuticals LLC, a specialty pharmaceuticalncompany developing life-saving therapeutics for rare cancers, has announced the issuance of UnitednStates Patents, No. 9,205,098 and No. 9,107,824. No. 9,205,098 describes the treatment of cancernpatients with the combination of chemotherapeutic agents Glufosfamide and gemcitabine. No. 9,107,824ndescribes the method and use of ILC (lipid-complexed cisplatin), via intraperitoneal administration, for thentreatment of patients with cancer, such as ovarian cancer.
Eleison Pharmaceuticals, Inc. today announced that the companynreached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessmentn(SPA) for a Phase 3 international randomized trial. This pivotal trial, which is expected to commence laternin 2010, will enroll patients with relapsed or refractory pancreatic cancer following prior chemotherapyntreatment. It is designed to evaluate the efficacy of Eleison drug candidate glufosfamide compared with anstandard control in the second-line treatment of pancreatic cancer.